[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633507":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":11,"locations":10,"responsibleParty":17,"collaborators":10,"id":22,"slug":10,"hasResults":23,"nctId":24,"briefTitle":25,"officialTitle":25,"acronym":10,"eligibilityCriteria":26,"healthyVolunteers":23,"sex":27,"minAge":28,"maxAge":10,"enrollmentInfo":29,"targetDuration":10,"studyType":32,"phases":10,"briefSummary":33,"conditions":34,"keywords":10,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":10},{"fullName":5,"class":6},"Huazhong University of Science and Technology","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":10},"Patients with malignancies receiving immunotherapy",null,[12],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},"Lingyan Xiao","CONTACT","027-15971474885","lingyanxiao@hust.edu.cn",{"type":18,"investigatorFullName":19,"investigatorTitle":20,"investigatorAffiliation":21,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Xianglin Yuan","Professor","Tongji Hospital","100633507",false,"NCT07527585","Study on Biomarkers of Immune-Related Adverse Events","Inclusion Criteria:\n\n1. Age \\>18 years;\n2. Karnofsky Performance Status (KPS) \\>60;\n3. Expected to receive at least one cycle of immune checkpoint inhibitor therapy;\n4. Expected survival \\>6 months.\n\nExclusion Criteria:\n\n1. Prior treatment with immune checkpoint inhibitors;\n2. Active autoimmune diseases (including systemic lupus erythematosus, inflammatory bowel disease, rheumatoid arthritis, myasthenia gravis, scleroderma, etc.);\n3. Use of systemic immunosuppressive agents within 14 days prior to enrollment (prednisone \\>10 mg\u002Fday or equivalent);\n4. Inability to provide biological samples.","ALL","18 Years",{"count":30,"type":31},440,"ESTIMATED","OBSERVATIONAL","1. To identify biomarkers of immune-related adverse events;\n2. To develop a predictive model for immune-related adverse events.",[35],"Immune-Related Adverse Events","NOT_YET_RECRUITING","2026-04-07",{"date":39,"type":40},"2026-04-14","ACTUAL",{"date":42,"type":31},"2026-04",{"date":44,"type":31},"2032-12",{"name":5,"class":6}]